Wikipedia:Version 1.0 Editorial Team/Pharmacology articles by quality log
This is a log of operations by a bot. The contents of this page are unlikely to need human editing. In particular, links should not be disambiguated as this is a historical record. |
June 10, 2024[edit]
Assessed[edit]
- Sibrafiban (talk) assessed. Quality assessed as Unassessed-Class. (rev · t) Importance assessed as Unknown-Class. (rev · t)
- Wellcome Research Laboratories (talk) assessed. Quality assessed as Unassessed-Class. (rev · t) Importance assessed as Unknown-Class. (rev · t)
June 9, 2024[edit]
Assessed[edit]
- Category:American pharmacists by populated place (talk) assessed. Quality assessed as Category-Class. (rev · t) Importance assessed as NA-Class. (rev · t)
- Category:American pharmacists by state (talk) assessed. Quality assessed as Category-Class. (rev · t) Importance assessed as NA-Class. (rev · t)
June 8, 2024[edit]
Reassessed[edit]
- 2′-Acetoxycocaine (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- 4-Hexylresorcinol (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Amylocaine (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Atazanavir/cobicistat (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Azoximer bromide (talk) reassessed. Quality rating changed from Stub-Class to C-Class. (rev · t)
- Bambermycin (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Belinostat (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Calcium dobesilate (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Imetelstat (talk) reassessed. Importance rating changed from Low-Class to Mid-Class. (rev · t)
June 7, 2024[edit]
Reassessed[edit]
- Antimotility agent (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Avacopan (talk) reassessed. Quality rating changed from Stub-Class to C-Class. (rev · t)
- Belzutifan (talk) reassessed. Quality rating changed from Stub-Class to C-Class. (rev · t)
- Bithionol (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Caplacizumab (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Cenegermin (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Concizumab (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Copper (64Cu) oxodotreotide (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Fabomotizole (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Fenticonazole (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Givosiran (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Indacaterol/glycopyrronium bromide/mometasone (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Inebilizumab (talk) reassessed. Quality rating changed from Stub-Class to C-Class. (rev · t)
- Istradefylline (talk) reassessed. Quality rating changed from Stub-Class to C-Class. (rev · t)
- Loncastuximab tesirine (talk) reassessed. Quality rating changed from Stub-Class to C-Class. (rev · t)
- Luspatercept (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Macimorelin (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Maralixibat chloride (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Mirvetuximab soravtansine (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Mobocertinib (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Mogamulizumab (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Monobactam (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Mosunetuzumab (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Nedosiran (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Odevixibat (talk) reassessed. Quality rating changed from Stub-Class to C-Class. (rev · t)
- Probucol (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Tofersen (talk) reassessed. Quality rating changed from Stub-Class to C-Class. (rev · t)
- Tralokinumab (talk) reassessed. Quality rating changed from Stub-Class to C-Class. (rev · t)
- Trilaciclib (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Velmanase alfa (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
Assessed[edit]
- KL-50 (talk) assessed. Quality assessed as Start-Class. (rev · t) Importance assessed as Low-Class. (rev · t)
- Draft:Shao Li (talk) assessed. Importance assessed as NA-Class. (rev · t)
- Draft:Terry Pirovolakis (talk) assessed. Importance assessed as NA-Class. (rev · t)
June 6, 2024[edit]
Renamed[edit]
- Draft:IM-250 renamed to IM-250.
Reassessed[edit]
- Acrivastine (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Apronal (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Epalrestat (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Methallylescaline (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Methysticin (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Naftifine (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Nalmexone (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- Tigilanol tiglate (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
- William Jay Schieffelin (talk) reassessed. Quality rating changed from Start-Class to C-Class. (rev · t)
June 5, 2024[edit]
Assessed[edit]
- Draft:Dan Berlau (talk) assessed. Importance assessed as NA-Class. (rev · t)
- Draft:IM-250 (talk) assessed. Importance assessed as NA-Class. (rev · t)
- Safety Pharmacology Society (talk) assessed. Quality assessed as Start-Class. (rev · t) Importance assessed as Unknown-Class. (rev · t)
Removed[edit]
- Draft:Craig Tooman (talk) removed.